# Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

> **NCT02857946** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Prevaglip (linagliptin)
- **DRUG:** Trajenta (linagliptin)

## Key facts

- **NCT ID:** NCT02857946
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-03
- **Final completion:** 2016-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02857946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02857946, "Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02857946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*